The purpose of this study is to determine how psoriatic nail disease is affected by secukinumab. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis in adults. While secukinumab has already been approved to treat psoriasis, the goal of this study is to look more closely at how it affects specific measures of psoriatic nail disease including imaging and patient reported measurements. Secukinumab is known as a biologic, and works by blocking the activity of a specific protein in the immune system, interleukin-17A, which is believed to be involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis.

You may be eligible for this study if you meet the following criteria:

• Conditions: Nail Psoriasis
• Age: 18 years - 99 years
• Gender: All